2017 Annual Meeting | C224 - Controversies in Multiple Sclerosis Therapy
| 07:00 AM - 07:20 AM | Speaker |
All Patients with CIS and RIS Should Start MS Therapy
Riley Bove, MD, FAAN |
| 07:20 AM - 07:30 AM | Q&A |
Questions and Answers
|
| 07:30 AM - 07:50 AM | Speaker |
All JCV Positive MS Patients Should Discontinue Natalizumab Therapy
Bruce A. Cree, MD, PhD, MAS, FAAN |
| 07:50 AM - 08:00 AM | Q&A |
Questions and Answers
|
| 08:00 AM - 08:20 AM | Speaker |
All Patients with MS Should Be Treated with Vitamin D Supplementation
Ellen M. Mowry, MD, FAAN |
| 08:20 AM - 08:30 AM | Q&A |
Questions and Answers
|
| 08:30 AM - 08:50 AM | Speaker |
Once Started, MS Therapies Should Be Continued for Life
Ellen M. Mowry, MD, FAAN |
| 08:50 AM - 09:00 AM | Q&A |
Questions and Answers
|
| Bruce A. Cree, MD, PhD, MAS, FAAN | The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neuron23. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal/Sandoz. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. The institution of Dr. Cree has received research support from Genentech. The institution of Dr. Cree has received research support from Kyverna. Dr. Cree has received publishing royalties from a publication relating to health care. |
| Ellen M. Mowry, MD, FAAN | Dr. Mowry has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Octave. Dr. Mowry has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SetPoint. The institution of Dr. Mowry has received research support from Genentech/Roche. The institution of Dr. Mowry has received research support from Biogen. Dr. Mowry has received publishing royalties from a publication relating to health care. |
| Riley Bove, MD, FAAN | Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme-Sanofi. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD-Serono. Dr. Bove has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cadenza. The institution of Dr. Bove has received research support from Biogen. The institution of Dr. Bove has received research support from Eli Lilly. The institution of Dr. Bove has received research support from Novartis. The institution of Dr. Bove has received research support from Roche Genentech. |